Hims & Hers reported first-quarter results with revenue up 4% and adjusted EBITDA down 51%. Both figures landed a low-single-digit percentage below guidance midpoints. Shares fell 9% after hours.
An increasing shift to digital healthcare underpins long-term growth potential for Hims’ subscribers.
By providing weight-loss offerings after the end of the branded semaglutide shortage, albeit at personalized doses, Hims runs the risk of legal actions from big pharmaceutical counterparts like Novo Nordisk as well as regulatory actions from the FDA.
|
Metric
|
HIMS
|
PRGO
|
NVO
|
|---|---|---|---|
Price/Earnings (Normalized) | 86.29 | 4.28 | 10.88 |
Price/Book Value | 13.87 | 0.61 | 6.25 |
Price/Sales | 2.87 | 0.36 | 3.84 |
Price/Cash Flow | 25.55 | 4.92 | 9.55 |
|
Metric
|
HIMS
|
PRGO
|
NVO
|
|---|---|---|---|
Quick Ratio | 1.46 | 1.06 | 0.54 |
Current Ratio | 1.69 | 2.72 | 0.79 |
Interest Coverage | — | −9.44 | — |
|
Metric
|
HIMS
|
PRGO
|
NVO
|
|---|---|---|---|
Return on Assets (Normalized) | 5.47% | 3.80% | 22.35% |
Return on Equity (Normalized) | 19.23% | 9.44% | 66.15% |
Return on Invested Capital (Normalized) | 7.20% | 6.73% | 37.39% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| Rqhftkzv | Txxlz | $67B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Xqlfdqtysb | Wpwxtq | $40B | |||
| Haleon PLC ADR
HLN
| Bgkyyjh | Rkl | $40B | |||
| Zoetis Inc Class A
ZTS
| Ckxdzttc | Chhmh | $33B | |||
| Viatris Inc
VTRS
| Mqqzpwp | Vszp | $19B | |||
| Elanco Animal Health Inc
ELAN
| Tbwv | Qpzs | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Jybtkvy | Zwdt | $11B | |||
| Prestige Consumer Healthcare Inc
PBH
| Xylwxrdx | Fjltvh | $2B | |||
| Perrigo Co PLC
PRGO
| Dszxrcrkv | Txkql | $2B |
/author-service-images-prod-us-east-1.publishing.aws.arc.pub/morningstar/b76d1412-e5af-4b94-8222-8cb66fe23dbe.jpg)
United States